Soligenix (SNGX) versus Jazz Pharmaceuticals PLC (JAZZ) Head to Head Contrast

Soligenix (OTC: SNGX) and Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.

Risk and Volatility

Soligenix has a beta of 1.7, meaning that its stock price is 70% more volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals PLC has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.

Valuation & Earnings

This table compares Soligenix and Jazz Pharmaceuticals PLC’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Soligenix N/A N/A N/A ($0.16) -13.81
Jazz Pharmaceuticals PLC $1.49 billion 5.50 $396.83 million $6.07 22.48

Jazz Pharmaceuticals PLC has higher revenue and earnings than Soligenix. Soligenix is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals PLC, indicating that it is currently the more affordable of the two stocks.


This table compares Soligenix and Jazz Pharmaceuticals PLC’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Soligenix -233.27% -196.47% -122.14%
Jazz Pharmaceuticals PLC 23.58% 22.92% 10.07%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Soligenix and Jazz Pharmaceuticals PLC, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Soligenix 0 0 2 0 3.00
Jazz Pharmaceuticals PLC 0 5 16 0 2.76

Soligenix presently has a consensus price target of $8.00, indicating a potential upside of 261.99%. Jazz Pharmaceuticals PLC has a consensus price target of $181.71, indicating a potential upside of 33.15%. Given Soligenix’s stronger consensus rating and higher probable upside, equities analysts plainly believe Soligenix is more favorable than Jazz Pharmaceuticals PLC.

Insider and Institutional Ownership

88.9% of Jazz Pharmaceuticals PLC shares are owned by institutional investors. 4.3% of Jazz Pharmaceuticals PLC shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.


Jazz Pharmaceuticals PLC beats Soligenix on 8 of the 11 factors compared between the two stocks.

Soligenix Company Profile

Soligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer. Its Vaccines/BioDefense business segment includes active development programs for RiVax, its ricin toxin vaccine candidate, OrbeShield, its GI acute radiation syndrome (GI ARS) therapeutic candidate, and SGX943, its melioidosis therapeutic candidate.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder. Its marketed products and late-stage product candidate are Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) Extended-Release Capsules and JZP-6 (sodium oxybate). Its other product candidates in clinical development are oral tablet forms of sodium oxybate; JZP-8 (intranasal clonazepam); JZP-4 (elpetrigine), and JZP-7 (ropinirole gel).

Receive News & Ratings for Soligenix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix Inc and related companies with's FREE daily email newsletter.

Leave a Reply